Cidara Therapeutics – 2025-11-14 - Increase Confidence 7/10

CDTX – Increase in Days/Weeks

Cidara Therapeutics reported a free cash flow of -$176.7M over the last twelve months, reflecting intense R&D investment, just days after announcing positive interim results from its Phase 2a trial of CD388, its universal influenza antiviral candidate.

Why This Matters

The company is burning significant cash without revenue, but the recent clinical momentum—particularly in its Cloudbreak platform—has intensified market speculation about near-term value inflection, such as a partnership, licensing deal, or expanded trial funding, all of which could catalyze a swift share price reaction despite weak fundamentals.

Key Insights

• Financial Burn: Free cash flow of -$176.7M (TTM) indicates reliance on future financing or partnerships to sustain operations.
• News Impact: Positive Phase 2a interim data for CD388 in universal flu prevention has triggered investor optimism and short-term speculative interest.
• Risk/Offset: High beta of 1.55 makes CDTX volatile and sensitive to market swings; any delay or setback could trigger sharp downside.

Practical Implications

• Bull Case: Upcoming data readout or partnership announcement could drive 20–30% upside in weeks.
• Bear Case: Lack of near-term revenue and cash burn could prompt dilution fears, leading to 15–20% correction if catalysts miss.
• Confidence: 7/10 – Strong analyst consensus (8 analysts, Strong Buy) supports upside, but fundamentals offer no cushion.

Prediction: increase

Reference:

• https://ir.cidara.com/news-releases/news-release-details/cidara-therapeutics-announces-positive-interim-phase-2a-data